Posttransplant Allosensitization in Low Immunological Risk Kidney and Kidney-Pancreas Graft Recipients
Table 2
Risk factors for anti-HLA antibodies positivity at 6 months by multivariable* logistic regression analysis.
Odds ratio
95% IC
value
Risk factors for anti-HLA (+)
ATG use
3.05
1.49–6.25
<0.01
Acute rejection
No episode
Reference
Steroid-sensitive
1.75
0.59–5.16
0.31
Steroid-insensitive
6.47
2.55–16.42
<0.01
Risk factors for anti-HLA class I (+)
ATG use
4.04
1.89–8.65
<0.01
Acute rejection
No episode
Reference
Steroid-sensitive
1.05
0.29–3.87
0.94
Steroid-insensitive
4.45
1.63–12.09
<0.01
Risk factor for anti-HLA class II (+)
Acute rejection
No episode
Reference
Steroid-sensitive
3.90
0.99–15.42
0.05
Steroid-insensitive
5.05
1.46–17.46
0.01
Variables included in the model are ATG use, time on dialysis, kidney-pancreas graft, acute rejection type, recipient age, and donor age, ABDR mismatches. HLA: human leukocyte antigen; IC: confidence interval; ATG: antithymocyte globulin.